Articles & Video
Post-event Report: Cell & Gene Therapy Bioprocessing & Commercialization 2020
We review the key highlights from the virtual conference, including analysis of the hottest sessions by BioProcess International magazine.
Ebook: The Future of the Cell and Gene Therapy Industry
What can we expect next from the cell and gene therapy sector? This ebook explores the potential paths ahead, from optimized CAR-T to automated bioprocessing.
Pharma’s role in maintaining cancer mortality progress during COVID-19
COVID-19 is threatening the progress made in reducing cancer mortality. Pharma has a pivotal role to play in helping patients and providers navigate the new reality of cancer treatment during the pandemic, and beyond.
BioProcess International Fall Digital Week 2020
We explore the agenda for the upcoming BioProcess International Fall Digital Week 2020.
BioProcess International 2020 Post-Event Report
Explore the highlights of the BioProcess International 2020 virtual conference in the post-event round-up.
Report: Partnering And Deal-Making in Pharma through the Pandemic
This Informa report explores how partnering and deal-making in the pharma industry has been impacted by COVID-19.
When to outsource manufacturing? Advice for cell and gene therapy developers
What scenarios could determine when is best to outsource manufacturing of cell and gene therapies to a CDMO?
REPORT: The Future of Healthcare Post COVID-19
In our latest report learn how healthcare organizations are adapting to succeed post COVID-19, from innovation to product development.
Viral vectors have biggest limitations in vector manufacturing, according to industry survey
Exploring results of our industry survey, we identify the biggest pain points in vector manufacturing experienced by cell and gene therapy professionals.
Vector manufacturing for cell and gene therapies: how should current platforms be changed?
What do we need from vector manufacturing platforms to deliver commercial scale therapies? We look at responses from industry insiders.
Novel analytical strategies and tools for cell and gene therapies - WHITEPAPER
What analytical techniques can be applied to production of cell therapies, gene therapies and gene-edited cell-therapies? This whitepaper looks at the latest examples.
Women in Pharma: 44% of pharma professionals think that women are under represented in their organization
44% of pharma professionals think that women are under represented in their organization according to new data from an Informa Connect Life Sciences study. Here we deep dive into the data.
Diversity and Inclusion in Biotech
The life science industry has a challenge to become more equal, diverse and inclusive. Join us at Diversity and Inclusion in Biotech, September 22nd and find out how TOGETHER we can make a difference.
Interview – J&J’s multi-pronged approach to life science innovation, partnerships, and advanced technologies
Dr. Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific, and Dr. Sharon Chan, Head of JLABS @ Shanghai discuss its support of startups, interests in diverse disease areas, the importance of collaborations and much more in this exclusive interview with EBD Group.
SURVEY: Partnering and Deal-Making in Biopharma through the Pandemic
We are conducting a huge study to gauge perspectives around biopharma deal-making during COVID-19 and the commercial ramifications of the pandemic. Take part here.
Automating cell and gene therapy manufacturing: challenges and approaches
With the pressure on to scale up manufacturing of cell and gene therapies, what steps should organizations take to optimize their processes with automation? We asked three industry experts for their advice.
42% of pharma industry believe cell and gene therapies to be most promising therapeutics
According to a recent study, 42% of pharma industry professionals predict cell and gene therapies are the therapeutic area that will see the fastest growth in the next 10 years.
Cell and Gene Therapy Report 2020: Viral and Non-viral Vectors
This report of our recent global industry survey reveals the biggest challenges in viral and non-viral vector manufacturing for cell and gene therapies.
Top Biotech Deals in China
Discover the deals transforming China biotech! More than $12 billion in biopharma financing, alliances, IPOs, and new funds have been generated so far this year in China. Learn the details of these deals when you read this new free infographic.
80% of life sciences professionals predict a COVID-19 vaccine will be approved within 18 months
How quickly to life sciences professionals predict a COVID-19 vaccine will be approved and what are the main obstacles? We explore.
The biggest breakthroughs in life sciences the last 10 years
CRISPR, CAR-T, immunotherapies, genome sequencing, AI - what is the biggest breakthrough in the life sciences in the last 10 years?